<div id="readability-page-1">11:43 AM EDT, 05/13/2026 (MT Newswires) -- Legend Biotech ( LEGN ) reported a solid Q1 for Carvykti, while focus is increasingly shifting to in vivo pipeline programs with potential updates expected in the coming months and additional clinical progress through 2026, RBC Capital Markets said.The brokerage said in a note Tuesday that it was a &#34;strong&#34; quarter for Carvykti with 21% excluding-US and 8% US quarter-over-quarter growth to $597 million, driven by increasing use in earlier lines of therapy, expansion into community treatment centers, and limited competitive pressure.Investor focus is shifting to in vivo CAR-T programs, with the pipeline now including at least three assets targeting GPRC5D, BCMA, and CD19/CD20. The CD19/CD20 program is of particular interest, with an update expected around mid-2026 at a key medical meeting, and given that no abstract was included in the general release, it could potentially be presented as a late breaker in June, the analyst said.&#34;We see Carvykti as a best-in-class CAR-T therapy for multiple myeloma,&#34; the analyst said, adding that the therapy could reach $2.75 billion in 2026 sales and $8 billion at peak sales.The investment firm sees Legend Biotech ( LEGN ) on track toward adjusted company-wide profitability in 2026.RBC raised Legend Biotech's ( LEGN ) price target from $62 to $64, with an outperform rating.Price: 28.78, Change: +0.52, Percent Change: +1.84 MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

LEGN

IBBQ

Legend Biotech reported a strong Q1 for Carvykti, with $597 million in sales, driven by increased use in therapy lines and expansion into treatment centers. RBC Capital Markets highlighted a shift in focus to in vivo CAR-T programs, particularly the CD19/CD20 asset, with updates expected in mid-2026. The firm raised Legend Biotech's price target from $62 to $64, maintaining an outperform rating, and anticipates adjusted profitability by 2026. Carvykti is projected to achieve $2.75 billion in sales in 2026 and $8 billion at peak.

fidelity

Legend Biotech

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

iShares US Pharma

Ark Genomic Revolution ETF

iShares Biotechnology ETF

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

iShares Global Healthcare

VG Health

ROYAL BANK OF CANADA

Legend Biotech Q1 Solid for Carvykti, Focus Shifts to In Vivo Pipeline, RBC Says